Prognostic value of genomic mutations in metastatic prostate cancer

• DOI: 10.1016/j.heliyon.2023.e13827
• Publication Date: 2023-02-17T17:32:27Z
• Authors: Honghui Zhu; Yi Ding; Hang Huang; Qi Lin; Wei Chen; Zhixian Yu
• Keywords: Olaparib

Metastatic prostate cancer (mPC) has a poor prognosis, and new treatment strategies are currently being offered for patients in clinical practice, but mPC is still incurable. A considerable proportion of with harbor homologous recombination repair (HRR) mutations, which may be more sensitive to poly (ADP-ribose) polymerase inhibitors (PARPis). We retrospectively included genomic data from 147 single center, total 102 circulating tumor DNA (ctDNA) samples 60 tissue samples. The frequency mutations was analyzed compared that Western cohorts. Cox analysis used assess progression-free survival (PFS) prognostic factors related prostate-specific antigen (PSA) after standard systemic therapy mPC. most frequently mutated gene the HRR pathway CDK12 (18.3%), followed by ATM (13.7%) BRCA2 (13.0%). remaining common ones were TP53 (31.3%), PTEN (12.2%), PIK3CA (11.5%). mutation close SU2C-PCF cohort (13.3%), CDK12, ATM, significantly higher than cohort: 4.7%, 7.3%, 5.3%, respectively. less responsive androgen receptor signaling (ARSIs), docetaxel, PARPi. helps predict PARPi efficacy. Additionally, (AR)-amplified do not respond well ARSIs, associated poorer docetaxel response. These findings support genetic profiling diagnosis guide stratification customize personalized treatment.